SOLACI-CACI 2021 | TCT II Session: Structural Heart Interventions

✔️ TCT Session in the SOLACI-CACI 2021 Congress.

👨‍🏫 Program:

  • 02:44 – Future of TAVR – Martin B. Leon
  • 36:27 – Future Developments in Trans-Catheter Mitral Valve Replacement – Juan F. Granada
  • 01:02:53 – Interventional Heart Failure – Dan Burkhoff

👉🏻 Chairperson: Aníbal Damonte & Jorge Belardi
👉🏻 Digital Moderator: Matías Sztejman
👉🏻 Panelists: Alcántara, Marco – Baccaro, Jorge -Barbagelata, Alejandro – Hurtado, Edgar – Leiva, Gustavo – Ribeiro, Henrique


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

SOLACI-CACI 2021 | SCAI Session

✔️ SCAI Session (Society for Cardiovascular Angiography and Interventions) in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 00:03 - STEMI: Approach to Left Main Culprit -...

SOLACI-CACI 2021 | CRT Session: Live Case From Washington

✔️ Watch again the CRT Session in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 00:03 - Live Case Medstar Washington Hospital Center - Operator: Lowel...

SOLACI-CACI 2021 | IAGS Session

✔️ Watch again the International Andreas Gruentzig Society (IAGS) Session in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 03:08 - PCI and TAVR: Which Lesions...

SOLACI-CACI 2021 | CBS Session

✔️ Watch again the CBS Session in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 00:01 - Live case from Nanjing First Hospital, NMU, Nanjing, China...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...